Are you watching this?

Alzheimer’s drug pipeline news: Biogen Inc. in partnership with Eisai Co. has released encouraging data about their new anti-amyloid monoclonal antibody therapy (lecanemab) currently in clinical trials. Lecanemab is intended for the treatment of mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD. It currently is under priority review by the FDA as part of the accelerated approval pathway and will seek traditional U.S. approval by the end of Q1 2023. If approved, its perceived overall clinical significance and long-term efficacy will play a major role in determining formulary placement and coverage status. Want to learn more about how ClearScript’s clinical teams watch the drug pipeline to proactively prepare pharmacy benefit plans? Follow the ClearScript on LinkedIn and learn more about how we can help.